Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process. Lori A. Leslie, MD: Hello, and welcome to CURE Expert Connections® ...

Although a single CLL-specific genomic aberration has not been identified, ≥80% of CLL cases do exhibit chromosomal abnormalities. 7 Four common genomic alterations exist and include aberrations on ...

Provide an overview of the current landscape of treatment-naïve CLL treatment options. Where do the BTK inhibitors fit into this landscape? Stay ahead of policy, cost, and value—subscribe to AJMC for ...

Please provide your email address to receive an email when new articles are posted on . Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) management demands a patient-centered approach ...

Lori A. Leslie, MD, an expert on CLL, talks about factors that influence treatment decisions. Lori A. Leslie, MD: Let’s talk about the types of patient factors we think about when selecting a ...

B-Chronic lymphocytic leukemia (CLL) is a relatively common B-cell malignancy that has a very heterogeneous clinical course, despite carrying the designation of “chronic,” which is a gross ...

The Chronic Lymphocytic Leukemia Market is set for significant expansion over the next decade. Valued at USD 5.4 billion in 2025, the market is projected to grow to USD 10.3 billion by 2035, ...

DUBLIN--(BUSINESS WIRE)--The "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. 'Relapsed Chronic Lymphocytic ...

DUBLIN--(BUSINESS WIRE)--The "B-Cell Chronic Lymphocytic Leukemia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. The report offers comprehensive Insight ...

LUGANO, SWITZERLAND, June 4, 2008 – Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session ...